well as age-related adherence issues. 3 In infants who are found to be HIV-infected, the early institution of antiretroviral regimens has become the standard of care to reduce mortality and the development of resistance mutations while preserving immunologic function. 4, 5 There are a number of issues that make treatment of HIV more problematic in the pediatric age appears that children suffer from enhanced acute as well as long-term drug toxicities. 6 In addition, adherence issues in infants, children and adolescents can affect the effectiveness of antiretroviral regimens, mandating the development of drugs more specifically appropriate for children, including characteristics such as improved tolerability.
Treatment recommendations
Children younger than 12 months of age 
Personal observations
The use of combination antiretroviral therapy in infants, children and adolescents has reduced morbidity and mortality, as well as improved quality of life of patients with perinatally acquired HIV, rendering HIV a chronic illness, with infected infants now surviving well into the third decade of their lives. 6 With the introduction of protease inhibitors in 1996, mortality dropped by 70% per year in pediatric patients capable of tolerating chronic treatment with three drugs from at least two of the major antiretroviral classes. 4 This achievement is attributable to the reduction in viral load and the consequent reconstitution of the immune system and drastic reduction in opportunistic infections that were previously frequently the causes of early death in perinatally HIV infected children. 9 The restoration of the immune system has also enabled children to avoid treatment with antimicrobial drugs that have their own significant toxicities, and adds to the adverse drug profiles of primary antiretroviral agents. When should we treat children with HIV? Oleske JM
